Latest Industry News & Trends

Market Scope provides comprehensive coverage of the ophthalmic market. Our news stories are a combination of public and proprietary content ranging from coverage of international meetings, surgeon survey results and trends, analysis of company financial reports and public medical registries, press releases, and interviews with executives. Register today to receive free weekly email updates, our top data chart, surgeon poll results, and much more. Locked content can be accessed through a subscription to our ophthalmic industry newsletters.

Deals News

12/6/2024
AIBreakingDealsDiagnosticFundusGlaucomaRetina
Avant, Ainnova Advancing Low-Cost Retinal Camera with AI Screening Software
Avant, Ainnova Advancing Low-Cost Retinal Camera with AI Screening Software

Nevada-based Avant Technologies and Ainnova Tech, of Houston, Texas, announced Nov. 20 that the two companies would advance Ainnova’s proprietary low-cost retinal camera packaged with the Vision AI...

11/27/2024
BreakingDealsGene TherapyRetina
Atsena Licenses LCA1 Gene Therapy Candidate to Nippon Shinyaku for US, Japan
Atsena Licenses LCA1 Gene Therapy Candidate to Nippon Shinyaku for US, Japan

Atsena Therapeutics announced Nov. 13 that it had granted exclusive commercial rights for its Leber congenital amaurosis type 1 (LCA1) gene therapy candidate ATSN-101 to Nippon Shinyaku in the US a...

11/15/2024
BreakingDealsRetina
Kalaris Will Merge with AlloVir and Advance Candidate for Exudative Retinal Disease
Kalaris Will Merge with AlloVir and Advance Candidate for Exudative Retinal Disease

Kalaris Therapeutics announced Nov. 8 that it would merge with biotech company AlloVir in an all-stock transaction to advance Kalaris’ next-generation anti-VEGF candidate TH103 for exudative retina...

11/15/2024
BreakingDealsOcular Cancer
Advancium Signs Option to License Retinoblastoma Candidate from Aileron
Advancium Signs Option to License Retinoblastoma Candidate from Aileron

Aileron Therapeutics and Advancium Health Network announced Oct. 31 an exclusive option agreement for Advancium to acquire ALRN-6924, a clinical-stage oncology agent developed by Aileron prior to i...

11/15/2024
BreakingChinaDealsRetina
Arctic Vision Licenses Chinese Rights for Xipere to Santen for $85 Million
Arctic Vision Licenses Chinese Rights for Xipere to Santen for $85 Million

Clearside Biomedical’s Asia-Pacific partner, Arctic Vision, announced Nov. 7 that it had licensed Chinese commercialization rights for ARVN001, marketed in the US as Xipere, to Santen Pharmaceutica...

11/14/2024
AAODealsEyeceleratorMeetingNewsletterRetina
Ophthalmology Continues to Draw Investors, Eyecelerator Meeting Shows; Retina Stands Out
Ophthalmology Continues to Draw Investors, Eyecelerator Meeting Shows; Retina Stands Out

Ophthalmology remains an appealing investment, driven largely by procedural growth. While hundreds of companies are working toward technology enhancements and innovative therapies, ophthalmology pr...

11/14/2024
AIDealsDiagnosticFundingGene TherapyGlaucomaNewsletterRetinaSurgical
EyePoint Leads Latest Ophthalmic Fundraising with $161 Million Public Offering
EyePoint Leads Latest Ophthalmic Fundraising with $161 Million Public Offering

EyePoint Pharmaceuticals led recent ophthalmic fundraising efforts with a $161 million upsized underwritten public offering. Proceeds in part will fund clinical development of Duravyu. Financing an...

11/14/2024
DealsGene TherapyNewsletterRetina
The New Opus Genetics Charts a Course to Gene Therapy Approval
The New Opus Genetics Charts a Course to Gene Therapy Approval

Ben Yerxa, PhD, and George Magrath, MD, say they have a way out of the jungle in which ocular gene therapy development has been trapped since the US FDA approved Luxturna in 2017. “You have to be r...

11/14/2024
DealsDry EyeNewsletter
NovaBay Accepts Higher Offer from PRN to Purchase Assets
NovaBay Accepts Higher Offer from PRN to Purchase Assets

NovaBay reported Nov. 6 that it had accepted a higher offer from PRN Physician Recommended Nutriceuticals, LLC, which revised its bid for NovaBay’s Avenova product line after a competing overture f...

11/14/2024
CataractClinical TrialDealsDiagnosticDry EyeFundingGene TherapyGlaucomaIndustryInstrumentsMicroscopesNewsletterOCTPresbyopiaRegulationRetinaStudySurgical
November 2024 Ophthalmic News Briefs
November 2024 Ophthalmic News Briefs

Heidelberg Engineering announced Oct. 14 that the US FDA had granted 510(k) clearance to its Flex Module for the Spectralis diagnostic imaging platform. The Flex Module mounts the Spectralis to a m...

11/8/2024
BreakingDealsDry Eye
NovaBay Accepts Higher Offer from PRN to Purchase Assets
NovaBay Accepts Higher Offer from PRN to Purchase Assets

NovaBay reported Nov. 6 that it had accepted a higher offer from PRN Physician Recommended Nutriceuticals, LLC, which revised its bid for NovaBay’s Avenova product line after a competing overture f...

11/8/2024
BreakingCataractDealsEuropePharma
DÁVI Licenses Clobetasol Propionate Post-op Drops from Formosa for Portugal
DÁVI Licenses Clobetasol Propionate Post-op Drops from Formosa for Portugal

Taiwan-based Formosa Pharmaceuticals announced Oct. 31 that it had entered into an exclusive licensing agreement with DÁVI Farmacêutica, of Portugal, for the rights there to market clobetasol propi...

11/1/2024
BreakingDealsDry Eye
NovaBay Receives Higher Asset Purchase Bid from RVL-Affiliated Company
NovaBay Receives Higher Asset Purchase Bid from RVL-Affiliated Company

NovaBay reported Oct. 29 that it had received a better offer for its assets than the one it had accepted from PRN Physician Recommended Nutriceuticals, LLC. NovaBay’s board determined that the unso...

11/1/2024
BreakingDealsPharmaRetina
Korean Companies GC Biopharma, Novelty Nobility to Collaborate on GA Drug Discovery
Korean Companies GC Biopharma, Novelty Nobility to Collaborate on GA Drug Discovery

South Korean companies GC Biopharma and Novelty Nobility announced Oct. 28 that they would jointly research and develop a novel treatment candidate for geographic atrophy (GA). The companies said a...

10/25/2024
BreakingDealsGene TherapyPresbyopiaRefractiveRetina
Ocuphire Pharma Acquires Opus Genetics, Will Operate Under Opus Name
Ocuphire Pharma Acquires Opus Genetics, Will Operate Under Opus Name

Ocuphire Pharma announced Oct. 22 that it would acquire Opus Genetics in an all-stock transaction. The combined company will operate under the Opus name and will trade on the Nasdaq under the ticke...

10/25/2024
BreakingCornealDealsDry EyeFundingStudy
Grifols, BARDA Partner on Ocular Immunoglobulin Drops for Sulfur Mustard Exposure
Grifols, BARDA Partner on Ocular Immunoglobulin Drops for Sulfur Mustard Exposure

Barcelona-basedGrifols reported Oct. 22 that it is partnering with the US government’s BARDA to test ocular surface immunoglobulin (OSIG) eye drops for their ability to treat ocular damage from sul...

10/18/2024
BreakingDealsPharmaPresbyopia
Orasis Licenses Qlosi Presbyopia Drops to Optus in Korea for $18 Million, Plus Royalties
Orasis Licenses Qlosi Presbyopia Drops to Optus in Korea for $18 Million, Plus Royalties

Orasis Pharmaceuticals announced Oct. 16 that it had licensed its Qlosi presbyopia drops to Optus Pharmaceuticals for the Korean market. Under the deal, Optus will pay upfront and milestone payment...

10/18/2024
BreakingDealsGlaucomaPharma
Nicox and Soleus Sign $16.5 Million Deal for Vyzulta Royalties, Equity Financing
Nicox and Soleus Sign $16.5 Million Deal for Vyzulta Royalties, Equity Financing

France’s Nicox announced Oct. 14 a deal with Soleus Capital under which Soleus will acquire Nicox’ royalties from the glaucoma treatment Vyzulta for $15 million, while providing $1.5 million in equ...

10/15/2024
AIDealsDiagnosticDigitalFundingMyopiaNewsletterPharmaPresbyopiaRetina
Orasis Leads Latest Ophthalmic Deals with $78 Million Financing
Orasis Leads Latest Ophthalmic Deals with $78 Million Financing

Orasis Pharmaceuticals led recent ophthalmic fundraising efforts with $78 million in Series D and structured capital to support the launch of Qlosi drops for presbyopia. Financing announced in the ...

10/15/2024
DealsESCRSEuropeFundingMeetingNewsletter
Investors Take Temperature of Ophthalmic Market at European Futures Forum
Investors Take Temperature of Ophthalmic Market at European Futures Forum

The 2024 Ophthalmology Futures European Forum reviewed the decline in ophthalmic deals in 2024 before offering presenting companies some guidance on how to advance their technology in such an envir...

10/15/2024
ChinaClinical TrialDealsDiagnosticDry EyeEuropeGene TherapyGlaucomaIndiaIndustryLaserNewsletterPerimetryRegulationRetinaSurgical
October 2024 Ophthalmic News Briefs
October 2024 Ophthalmic News Briefs

Oculus has announced the addition of frequency doubling perimetry (FDP) to its Easyfield VR visual field diagnostic headset. The German ophthalmic diagnostic company, with US headquarters in Arling...

10/15/2024
DealsDry EyeNewsletter
NovaBay to Sell Avenova Products for $9.5 Million as Part of Dissolution Plan
NovaBay to Sell Avenova Products for $9.5 Million as Part of Dissolution Plan

NovaBay Pharmaceuticals has agreed to sell its Avenova products to PRN Physician Recommended Nutriceuticals for $9.5 million in cash, the companies announced Sept. 20. The deal is expected to close...

10/4/2024
BreakingDealsDry EyeEuropeRegulation
EU Regulators Approve Vevizye from Novaliq; Théa Will Commercialize Dry Eye Drop
EU Regulators Approve Vevizye from Novaliq; Théa Will Commercialize Dry Eye Drop

Germany’s Novaliq announced Oct. 2 that the European Commission had approved its dry eye treatment Vevizye (cyclosporine ophthalmic solution) 0.1%. The product is indicated for the treatment of mod...

10/4/2024
BreakingDealsFundingRetina
Boehringer Ingelheim to Advance Surrozen’s Bi-specific Antibody in Retinal Disease
Boehringer Ingelheim to Advance Surrozen’s Bi-specific Antibody in Retinal Disease

Surrozen announced Sept. 24 that development partner Boehringer Ingelheim will advance SZN-413, a bi-specific antibody targeting retinal vascular disease. The milestone triggers a $10 million payme...

10/4/2024
BreakingDealsRetina
Nanoscope Licenses Optogenetic Technology from Max Planck Innovation
Nanoscope Licenses Optogenetic Technology from Max Planck Innovation

Nanoscope Therapeutics announced Sept. 30 that it had acquired a license for CatCh optogenetic technology from Max Planck Innovation, the technology transfer arm of the Max Planck Society. Financia...

9/27/2024
BreakingDealsGlaucomaRetina
Nicox, Glaukos Sign Research and Option Agreement for Glaucoma Candidate
Nicox, Glaukos Sign Research and Option Agreement for Glaucoma Candidate

France’s Nicox announced Sept. 23 that it had signed an exclusive research and license option agreement with Glaukos for NCX 1728, Nicox’s novel nitric oxide (NO)-donating phosphodiesterase-5 (PDE5...

9/27/2024
BreakingDealsInstrumentsRetinaSurgical
Microsurgical Technology (MST) to Commercialize Vista Vitrectomy Products
Microsurgical Technology (MST) to Commercialize Vista Vitrectomy Products

Microsurgical Technology (MST) announced Sept. 17 that it had partnered with Vista Ophthalmics to commercialize Vista’s products—the Vista 1-Step vitrectomy probe and the Vista IS for maintaining t...

9/20/2024
BreakingDealsPrivate Equity
Bausch + Lomb Explores Sale to Separate from Bausch Health
Bausch + Lomb Explores Sale to Separate from Bausch Health

Bausch + Lomb is working with Goldman Sachs to explore a sale of the company, the Financial Times reported Sept. 14, with private equity the most likely buyer. The move is being evaluated as a way ...

9/20/2024
BreakingDealsDry Eye
NovaBay to Sell Avenova Products for $9.5 Million as Part of Dissolution Plan
NovaBay to Sell Avenova Products for $9.5 Million as Part of Dissolution Plan

NovaBay Pharmaceuticals has agreed to sell its Avenova products to PRNPhysician Recommended Nutriceuticals for $9.5 million in cash, the companies announced Sept. 20. The deal is expected to close ...

9/20/2024
AllergyBreakingChinaDealsRegulation
Nicox Reports that Ocumension Has Gained Approval for Zerviate in China
Nicox Reports that Ocumension Has Gained Approval for Zerviate in China

France’s Nicox announced Sept. 18 that partner Ocumension Therapeutics had received regulatory approval in China to commercialize Nicox’ Zerviate (cetirizine ophthalmic solution) 0.24% for ocular i...

9/20/2024
BreakingDealsGlaucomaPharma
Ripple, AbbVie to Collaborate on Fully Biodegradable Bimatoprost Implant for Glaucoma
Ripple, AbbVie to Collaborate on Fully Biodegradable Bimatoprost Implant for Glaucoma

Ripple Therapeutics, of Toronto, Canada, announced Sept. 17 that it had signed a collaboration agreement with AbbVie to develop RTC-620, a fully biodegradable sustained-release intracameral bimatop...

9/19/2024
CataractDealsGlaucomaNewsletterPharma
Visiox to Merge with Ocuvex to Advance Two Ophthalmic Drug Candidates
Visiox to Merge with Ocuvex to Advance Two Ophthalmic Drug Candidates

Visiox Pharmaceuticals announced Aug. 19 that it had agreed to merge with Ocuvex Therapeutics, a privately held company in New Hyde Park, New York. A Visiox news release said Ocuvex has a pipeline ...

9/19/2024
AIDealsDiagnosticNewsletterRetina
Revenio’s iCare Subsidiary Acquires AI Screening Company Thirona Retina
Revenio’s iCare Subsidiary Acquires AI Screening Company Thirona Retina

Finland’s Revenio Group announced Aug. 20 that its iCare subsidiary had assumed ownership of the Dutch artificial intelligence (AI) software company Thirona Retina. iCare had made a minority invest...

8/30/2024
AIBreakingDealsDiagnosticEuropeGlaucomaRetina
Revenio’s iCare Subsidiary Acquires AI Screening Company Thirona Retina
Revenio’s iCare Subsidiary Acquires AI Screening Company Thirona Retina

Finland’s Revenio Group announced Aug. 20 that its iCare subsidiary had assumed ownership of the Dutch artificial intelligence (AI) software company Thirona Retina. iCare had made a minority invest...

8/23/2024
BreakingDealsGlaucomaPharma
Visiox to Merge with Ocuvex to Advance Candidates for Glaucoma, Postsurgical Pain and Inflammation
Visiox to Merge with Ocuvex to Advance Candidates for Glaucoma, Postsurgical Pain and Inflammation

Visiox Pharmaceuticals announced Aug. 19 that it had agreed to merge with Ocuvex Therapeutics, a privately held company in New Hyde Park, New York. A Visiox news release said Ocuvex has a pipeline ...

8/21/2024
ChinaDealsDry EyeNewsletterPharma
Ocumension Acquires Rights to Alcon Eye Drops in Exchange for Equity Stake
Ocumension Acquires Rights to Alcon Eye Drops in Exchange for Equity Stake

China’s Ocumension Therapeutics announced Aug. 13 that it would acquire or secure Chinese rights to a portfolio of Alcon dry eye treatments and procedural drops. In exchange, Ocumension will issue ...

8/21/2024
CataractDealsLaserNewsletter
Lensar Ends Collaboration with Oertli for Phaco Portion of Ally Cataract System
Lensar Ends Collaboration with Oertli for Phaco Portion of Ally Cataract System

Lensar has terminated its collaboration agreement with Swiss company Oertli, according to a filing Aug. 5 with the US Securities and Exchange Commission. The two had been developing the Ally Adapti...

8/21/2024
BiosimilarsCornealDealsDry EyeEuropeGene TherapyGenericsIndustryLow VisionNewsletterOcular CancerPharmaPresbyopiaRegulationRetina
August 2024 Ophthalmic News Briefs
August 2024 Ophthalmic News Briefs

Ireland-based Mallinckrodt announced Aug. 6 that its H.P. Acthar Gel single-dose prefilled SelfJect injector was available in the US. The US FDA approved the supplemental new drug application for t...

8/16/2024
BreakingChinaDealsDry EyePharma
Ocumension Acquires Rights to Alcon Eye Drops in Exchange for 16.7 Percent Equity Stake
Ocumension Acquires Rights to Alcon Eye Drops in Exchange for 16.7 Percent Equity Stake

China’s Ocumension Therapeutics announced Aug. 13 that it would acquire or secure Chinese rights to a portfolio of Alcon dry eye treatments and procedural drops. In exchange, Ocumension will issue ...

8/16/2024
BreakingCornealDealsPharma
Santen Licenses Cloudbreak Topical Pterygium Candidate for Japan, Korea, and Southeast Asia
Santen Licenses Cloudbreak Topical Pterygium Candidate for Japan, Korea, and Southeast Asia

Japan’s Santen announced Aug. 6 that it had signed an agreement to license CBT-001, a topical pterygiumtreatment candidate from Cloudbreak Pharma. The deal covers the territories of Japan, South Ko...

8/8/2024
BreakingCataractDealsSurgical
Lensar Ends Collaboration with Oertli for Phaco Portion of Ally Cataract System
Lensar Ends Collaboration with Oertli for Phaco Portion of Ally Cataract System

Lensar has terminated its collaboration agreement with Swiss company Oertli, according to a filing Aug. 5 with the US Securities and Exchange Commission. The two had been developing the Ally Adapti...

8/9/2024
BreakingCataractDealsDry EyePharmaSurgical
Formosa Licenses Clobetasol Propionate Drops to Apotex for Canada
Formosa Licenses Clobetasol Propionate Drops to Apotex for Canada

Taiwan-based Formosa Pharmaceuticals announced Aug. 5 that it had agreed to license to Apotex exclusive rights to market clobetasol propionate 0.05% eye drops for postsurgical inflammation and pain...

8/2/2024
BreakingDealsDry Eye
Eyenovia, SGN Nanopharma Will Collaborate on Chronic Dry Eye Candidate with Optejet Microdoser
Eyenovia, SGN Nanopharma Will Collaborate on Chronic Dry Eye Candidate with Optejet Microdoser

Eyenovia, of New York, announced July 30 that it had entered into a collaboration agreement with SGN Nanopharma to develop SGN’s micellar nanoparticle platform-based cyclosporine formulation for us...

7/26/2024
BreakingCornealDealsDiagnosticDry EyeSurgical
Bausch + Lomb Acquires Dry Eye Diagnostic Company Trukera Medical
Bausch + Lomb Acquires Dry Eye Diagnostic Company Trukera Medical

Bausch + Lomb announced July 23 that it had acquired dry eye diagnostic company Trukera Medical from its private equity owner, AccelMed Partners, and other shareholders. No financial details were d...

7/26/2024
BreakingCornealDealsDry EyeIndustry
Eyenovia, Senju Will Collaborate on Chronic Dry Eye Candidate with Optejet Microdoser
Eyenovia, Senju Will Collaborate on Chronic Dry Eye Candidate with Optejet Microdoser

Eyenovia, of New York, announced July 23 that it had entered into a collaboration agreement with Japan’s Senju Pharmaceutical to develop Senju’s corneal epithelial wound healing candidate, SJP-0035...

7/23/2024
AcquisitionsDealsFundingNewsletter
Q2-2024 Ophthalmic Deals Total More Than $1.6 Billion, Include One Strategic Purchase
Q2-2024 Ophthalmic Deals Total More Than $1.6 Billion, Include One Strategic Purchase

Ophthalmic deals in Q2-2024 reached over $1.6 billion and involved 19 transactions. This compares with $7.0 billion from 25 transactions in Q2-2023 and $2.0 billion from 17 transactions in Q1-2024....

7/23/2024
AcquisitionsDealsNewsletterPharma
ANI to Acquire Alimera Sciences, Maker of Iluvien and Yutiq, for $381 Million
ANI to Acquire  Alimera Sciences, Maker of Iluvien and Yutiq, for $381 Million

ANI Pharmaceuticals announced June 24 that it would acquire Alimera Sciences, maker of Iluvien and Yutiq, in a deal worth $381 mil-lion up front. The deal is expected to close in late Q3-2024, the ...

7/23/2024
BiosimilarsClinical TrialCornealDealsDry EyeEuropeGene TherapyGlaucomaIndiaIndustryMyopiaNewsletterRegulationRetina
July 2024 Ophthalmic News Briefs
July 2024 Ophthalmic News Briefs

Bausch + Lomb announced July 23 that it had acquired dry eye diagnostic company Trukera Medical from its private equity owner, AccelMed Partners, and other shareholders. No financial details were d...

7/19/2024
BreakingDealsDiagnosticOCT
EssilorLuxottica Acquires Majority Stake in Diagnostics Maker Heidelberg 
EssilorLuxottica Acquires Majority Stake in Diagnostics Maker Heidelberg

Eyewear conglomerate EssilorLuxottica announced July 17 that it had agreed to acquire an 80 percent stake in Heidelberg Engineering, a leader in ophthalmic diagnostic imaging. Financial details wer...

7/19/2024
BreakingDealsGene TherapyRetina
Beacon Will Evaluate Abeona’s AAV204 Capsid for Select Ophthalmic Indications
Beacon Will Evaluate Abeona’s AAV204 Capsid for Select Ophthalmic Indications

Beacon Therapeutics will evaluate Abeona Therapeutics’ patented AAV204 capsid for potential gene therapies for select ophthalmic indications, the companies announced July 11. AAV204, a novel AAV ca...

7/11/2024
BreakingCataractDealsEuropeRefractiveSurgical
Ophthalmology Chain Clínica Baviera Enters UK Market with Acquisition of Optimax
Ophthalmology Chain Clínica Baviera Enters UK Market with Acquisition of Optimax

European ophthalmology chain Clínica Baviera has extended its reach into the UK with the purchase of Optimax. Optimax (Eye Hospitals Group and subsidiaries) operates 19 clinics under the Optimax an...

7/5/2024
BreakingCornealDealsFundingRefractive
J&J Leads Series A Round for Crosslinking Tech Developer TecLens
J&J Leads Series A Round for Crosslinking Tech Developer TecLens

Johnson & Johnson is the lead investor in a Series A funding round for Stamford, Connecticut-based TecLens, developer of a new crosslinking technology, J&J announced June 21. The technology is inte...

7/5/2024
BreakingDealsDry Eye
Kane Biotech Licenses Biofilm Dispersion Enzyme to I-Med for Dry Eye
Kane Biotech Licenses Biofilm Dispersion Enzyme to I-Med for Dry Eye

Kane Biotech announced June 25 that I-Med Pharma had licensed its DispersinB biofilm dispersion technology to incorporate into its products to relieve dry eye. It’s the first commercial agreement f...

7/5/2024
BreakingDealsIndiaPharmaRetina
RevOpsis Enlists India’s Kemwell Biopharma to Manufacture Wet AMD Candidate
RevOpsis Enlists India’s Kemwell Biopharma to Manufacture Wet AMD Candidate

RevOpsis Therapeutics, of San Carlos, California, announced June 17 that it had entered into a strategic manufacturing partnership with India’s Kemwell Biopharma. The deal aims to accelerate develo...

6/28/2024
AcquisitionsBreakingDealsPharma
ANI Pharmaceuticals to Acquire Alimera Sciences, Maker of Iluvien and Yutiq, for $381 Million
ANI Pharmaceuticals to Acquire Alimera Sciences, Maker of Iluvien and Yutiq, for $381 Million

ANI Pharmaceuticals announced June 24 that it would acquire Alimera Sciences, maker of Iluvien and Yutiq, in a deal worth $381 million up front. The deal is expected to close in late Q3-2024, the c...

6/24/2024
CornealDealsDiagnosticNewsletter
Eversight Partners with LighTopTech to Improve Imaging of Eye Tissues
Eversight Partners with LighTopTech  to Improve Imaging of Eye Tissues

Global nonprofit eye bank Eversight announced June 5 a four-year partnership with LighTopTech to improve imaging for eye tissues in clinical and research settings. Eversight will integrate LighTopT...

6/24/2024
DealsDiagnosticFundingGene TherapyGlaucomaNewsletterPharmaRetinaTelehealth
Opthea Leads Latest Fundraising with $113.2M Placement, Entitlement Offer
Opthea Leads Latest Fundraising with $113.2M Placement, Entitlement Offer

Opthea led recent ophthalmic fundraising efforts with a $113.2 million placement and entitlement offer, as it continues to advance its wet AMD candidate. Financing announced in the past four weeks ...

6/25/2024
DealsNewsletterPharmaRetina
Merck to Acquire Retinal Drug Developer EyeBio in Deal Worth up to $3 Billion
Merck to Acquire Retinal Drug Developer EyeBio in Deal Worth up to $3 Billion

Merck, of Rahway, New Jersey, announced May 29 that it was acquiring Eyebiotech Limited (EyeBio) for an upfront payment of $1.3 billion and up to $1.7 billion in future milestone payments. The deal...

6/24/2024
CataractClinical TrialData SecurityDealsDiagnosticDry EyeGene TherapyGlaucomaIOLIndustryMyopiaNewsletterRefractiveRegulationRetinaSurgical
June 2024 Ophthalmic News Briefs
June 2024 Ophthalmic News Briefs

Japan’s Nidek announced June 3 that it had launched the RS-1 Glauvas OCT system. The device is CE marked as a Class IIa device. Nidek said the RS-1 Glauvas’ streamlined workflow and advanced analyt...

6/21/2024
BreakingCornealDealsDiagnostic
Eversight Partners with LighTopTech to Improve Imaging of Eye Tissues
Eversight Partners with LighTopTech to Improve Imaging of Eye Tissues

Global nonprofit eye bank Eversight announced June 5 a four-year partnership with LighTopTech to improve imaging for eye tissues in clinical and research settings. Eversight will integrate LighTopT...

6/7/2024
DealsRefractiveSurgical
Sightpath Medical Acquires LASIK Services Business PennVista
Sightpath Medical Acquires LASIK Services Business PennVista

Sightpath Medical announced May 30 that it had acquired PennVista, a LASIK services business operating in Pennsylvania, Ohio, West Virginia, Indiana, and Michigan. Financial details were not disclo...

5/31/2024
BreakingDealsPharmaRetina
Merck to Acquire Retinal Drug Developer EyeBio in Deal Worth up to $3 Billion
Merck to Acquire Retinal Drug Developer EyeBio in Deal Worth up to $3 Billion

Merck, of Rahway, New Jersey, announced May 29 that it was acquiring Eyebiotech Limited (EyeBio) for an upfront payment of $1.3 billion and up to $1.7 billion in future milestone payments. The deal...

5/31/2024
BreakingDealsRetina
HanAll Licenses Turn Bio mRNA Technology for Eye and Ear Diseases
HanAll Licenses Turn Bio mRNA Technology for Eye and Ear Diseases

South Korea-based HanAll Biopharma announced May 28 that it had licensed Turn Biotechnologies’ epigenetic reprogramming technology for eye and ear diseases. The company said the deal could be worth...

5/22/2024
AcquisitionsDealsGlaucomaLaserNewsletter
Alcon to Acquire Glaucoma Laser Company Belkin Vision for up to $335M
Alcon to Acquire Glaucoma Laser Company Belkin Vision for up to $335M

Alcon is acquiring Israel’s Belkin Vision, maker of the Eagle laser for glaucoma, for up to $335 million, according to reports. The value of the transaction was first estimated in a story dated May...

5/22/2024
DealsNewsletterPharmaRetina
Xbrane, Stada Partner with Valorum to Commercialize Ranibizumab Biosimilar in US
Xbrane, Stada Partner with Valorum to Commercialize Ranibizumab Biosimilar in US

Partners Xbrane Biopharma, of Sweden, and Germany’s Stada announced May 10 that they had entered into an exclusive licensing agreement with biosimilar company Valorum Biologics to market their rani...

5/22/2024
AIDealsDiagnosticGlaucomaMeetingNewsletterRetinaStudy
Artificial Intelligence Takes Leading Role at 2024 ARVO Meeting
Artificial Intelligence Takes Leading Role at 2024 ARVO Meeting

Artificial intelligence was a prominent topic at the 2024 ARVO meeting. Discussions ranged from using AI in published ophthalmic research to employing it in early detection and monitoring of eye di...

5/22/2024
AIDealsDiagnosticNewsletter
New Topcon Healthcare CEO, Latest Partnerships Stress Focus on ‘Oculomics’
New Topcon Healthcare CEO, Latest Partnerships Stress Focus on ‘Oculomics’

Topcon Healthcare announced April 26 that it had appointed Ali Tafreshi as CEO and president. The company said Tafreshi will lead the company’s focus on “oculomics”—diagnosing not just eye disease ...

5/17/2024
BiosimilarsBreakingDealsRetina
Xbrane, Stada Partner with Valorum to Commercialize Ranibizumab Biosimilar Candidate in US
Xbrane, Stada Partner with Valorum to Commercialize Ranibizumab Biosimilar Candidate in US

Partners Xbrane Biopharma, of Sweden, and Germany’s Stada announced May 10 that they had entered into an exclusive licensing agreement with biosimilar company Valorum Biologics to market their rani...

5/17/2024
BreakingCataractDealsPharma
Formosa Licenses Clobetasol Propionate Drops to Tabuk Pharmaceuticals for MENA Region
Formosa Licenses Clobetasol Propionate Drops to Tabuk Pharmaceuticals for MENA Region

Taiwan-based Formosa Pharmaceuticals announced May 9 that it had entered into an exclusive licensing agreement with Tabuk Pharmaceuticals to market clobetasol propionate 0.05% eye drops for post-su...

5/10/2024
AcquisitionsBreakingDealsGlaucomaLaser
Alcon to Acquire Glaucoma Laser Company Belkin Vision for up to $335 Million
Alcon to Acquire Glaucoma Laser Company Belkin Vision for up to $335 Million

Alcon is acquiring Israel’s Belkin Vision, maker of the Eagle laser for glaucoma, for up to $335 million, according to reports. The value of the transaction was first estimated in a story dated May...

5/3/2024
AcquisitionsBreakingDealsLow VisionProsthesisRetina
California-Based Science Corporation Acquires Pixium Vision’s Prima Implant
California-Based Science Corporation Acquires Pixium Vision’s Prima Implant

Science Corporation, of Alameda, California, reported April 25 that it had acquiredthe IP and related assets for the Prima retinal implant, developed by Pixium Vision SA, of France. Terms of the de...

4/24/2024
DealsFundingNewsletter
Retinal Pharmaceutical Transactions Drive Ophthalmic Deals in First Quarter of 2024
Retinal Pharmaceutical Transactions Drive Ophthalmic Deals in First Quarter of 2024

Ophthalmic deals in Q1-2024 reached over $2.1 billion and involved 20 transactions. This compares with $2.0 billion from 17 transactions in Q1-2023 and $570 million from 12 transactions in Q4-2023....

4/24/2024
DealsIndiaNewsletter
Warburg Pincus Buys Controlling Stake in India’s Appasamy
Warburg Pincus Buys Controlling Stake in India’s Appasamy

US-based private equity firm Warburg Pincus and Appasamy Associates announced April 10 that Warburg had bought a controlling stake in the Indian ophthalmic company. Financial details were not discl...

4/24/2024
AcquisitionsDealsNewsletterRetina
ABVC BioPharma Sells Global Rights to Vitreous Substitute to ForSeeCon Eye for $30 Million Up Front
ABVC BioPharma Sells Global Rights to Vitreous Substitute to ForSeeCon Eye for $30 Million Up Front

ABVC BioPharma announced March 26 that it had agreed to license its ophthalmology pipeline, including the vitreous substitute candidate Vitargus, to ForSeeCon Eye. ABVC, of Fremont, California, say...

4/24/2024
CataractDealsIndustryNewsletterPharma
Eyenovia Explores Strategic Alternatives as it Rolls Out Mydcombi, Postsurgical Steroid
Eyenovia Explores Strategic Alternatives  as it Rolls Out Mydcombi,  Postsurgical Steroid

Eyenovia reported April 8 that it is exploring strategic alternatives to maximize shareholder value, even as it rolls out Mydcombi for pupil dilation and prepares to launch its clobetasol propionat...

4/24/2024
Clinical TrialCornealData SecurityDealsDiagnosticDry EyeEnvironmentFundingGlaucomaIOLIndustryMicroscopesNewsletterRegulationRetina
April 2024 Ophthalmic News Briefs
April 2024 Ophthalmic News Briefs

Alexion, the rare disease unit of AstraZeneca, announced March 25 that the US FDA had approved its long-acting C5 complement inhibitor Ultomiris (ravulizumab-cwvz) for adults with neuromyelitis opt...

4/12/2024
BreakingDealsIndiaIndustry
US Private Equity Firm Warburg Pincus Buys Controlling Stake in India’s Appasamy
US Private Equity Firm Warburg Pincus Buys Controlling Stake in India’s Appasamy

US-based private equity firm Warburg Pincus and Appasamy Associates announced April 10 that Warburg had bought a controlling stake in the Indian ophthalmic company. Financial details were not discl...

4/12/2024
BreakingCataractDealsIndustryPharma
Eyenovia Explores Strategic Alternatives as it Rolls Out Mydcombi, Postsurgical Steroid
Eyenovia Explores Strategic Alternatives as it Rolls Out Mydcombi, Postsurgical Steroid

Eyenovia reported April 8 that it is exploring strategic alternatives to maximize shareholder value, even as it rolls out Mydcombi for pupil dilation and prepares to launch its clobetasol propionat...

4/5/2024
BreakingCornealDeals
Optical Chain to Exclusively Offer Verséa’s Biovance Ocular Allografts
Optical Chain to Exclusively Offer Verséa’s Biovance Ocular Allografts

West Point Optical Group, which operates 86 Pearle Vision clinics in 13 states, announced April 3 that it had reached an agreement with Verséa Ophthalmics to offer Verséa’s Biovance and Biovance 3L...

3/29/2024
BreakingCornealDealsRetinaSurgical
ABVC BioPharma Sells Global Rights to Vitreous Substitute to ForSeeCon Eye for $30 Million Up Front
ABVC BioPharma Sells Global Rights to Vitreous Substitute to ForSeeCon Eye for $30 Million Up Front

ABVC BioPharma announced March 26 that it had agreed to license its ophthalmology pipeline, including the vitreous substitute candidate Vitargus, to ForSeeCon Eye. ABVC, of Fremont, California, say...

3/29/2024
BreakingDeals
Provectus Licenses from University of Miami a Photodynamic Antimicrobial Treatment with Rose Bengal Sodium
Provectus Licenses from University of Miami a Photodynamic Antimicrobial Treatment with Rose Bengal Sodium

Provectus Biopharmaceuticals announced March 27 that it had entered into an agreement with the University of Miami for an exclusive worldwide license of a photodynamic antimicrobial therapy (PDAT) ...

3/22/2024
BreakingDealsDry EyePharmaRevenueSurgical
2023 Ophthalmic Revenue Roundup for Harrow, Alimera Sciences, and EyePoint
2023 Ophthalmic Revenue Roundup for Harrow, Alimera Sciences, and EyePoint

Nashville, Tennessee-based Harrow reported March 19 that its 2023 revenue was $130.2 million, a 47 percent increase over $88.6 million in 2022. The company generated record quarterly revenue in Q4-...

3/21/2024
DealsNewsletter
Athyrium Takes Control of Upneeq Maker RVL Inc. as Parent Winds Down
Athyrium Takes Control of Upneeq Maker RVL Inc. as Parent Winds Down

RVL Pharmaceuticals Inc., of New Jersey, formerly a subsidiary of publicly held RVL Pharmaceuticals plc, is now owned by Athyrium Capital Management after emerging from Chapter 11 bankruptcy procee...

3/21/2024
CornealDealsDry EyeIOLIndustryNewsletterRegulationRetina
March 2024 Ophthalmic News Briefs
March 2024 Ophthalmic News Briefs

Germany’s VSY Biotechnology launched its Enova Maestro trifocal toric preloaded intraocular lens (IOL) at the European Society of Cataract and Refractive Surgeons (ESCRS) Winter Meeting, held Feb. ...

3/15/2024
BreakingDealsIndustry
Athyrium Takes Control of Upneeq Maker RVL Inc. as Parent Winds Down
Athyrium Takes Control of Upneeq Maker RVL Inc. as Parent Winds Down

RVL Pharmaceuticals Inc., of New Jersey, formerly a subsidiary of publicly held RVL Pharmaceuticals plc, is now owned by Athyrium Capital Management after emerging from Chapter 11 bankruptcy procee...

3/15/2024
BreakingCataractDealsDry EyePharma
NovaBay, Eyenovia Team Up to Co-promote Ophthalmic Products
NovaBay, Eyenovia Team Up to Co-promote Ophthalmic Products

Eyenovia and NovaBay Pharmaceuticals announced March 13 the signing of a co-promotion agreement to commercialize their prescription ophthalmic products. Under the agreement, NovaBay will market Eye...

2/23/2024
BreakingClinical TrialCornealDeals
Eversight Partners with Emmecell to Advance Corneal Cell Therapies
Eversight Partners with Emmecell to Advance Corneal Cell Therapies

Global nonprofit eye bank Eversight and Emmecell announced Feb. 20 that they would collaborate to advance cell therapies for corneal treatment. Emmecell, of Menlo Park, California, is developing EO...

2/22/2024
AcquisitionsDealsNewsletterRetina
Sandoz Acquires Biosimilar Cimerli from Coherus for $170M Up Front
Sandoz Acquires Biosimilar Cimerli from Coherus for $170M Up Front

Swiss drugmaker Sandoz announced Jan. 22 that it had signed an agreement to acquire the US ranibizumab (Lucentis) biosimilar Cimerli from Coherus BioSciences for $170 million up front. The deal inc...

2/22/2024
DealsFundingGene TherapyGlaucomaNewsletterRetinaSurgical
4DMT Leads Latest Ophthalmic Fundraising with $300 Million Public Offering
4DMT Leads Latest Ophthalmic Fundraising with $300 Million Public Offering

4D Molecular Therapeutics led recent ophthalmic fundraising efforts with a $300 million upsized public offering to continue advancing its retinal gene therapy candidate. Financing announced in the ...

2/22/2024
CataractClinical TrialCornealDealsDiagnosticDry EyeGene TherapyGlaucomaIOLIndustryNewsletterPresbyopiaRegulationRetinaSurgical
February 2024 Ophthalmic News Briefs
February 2024 Ophthalmic News Briefs

Amneal Pharmaceuticals announced Jan. 10 that it had received US FDA approval for and launched generic fluorometholone eye drops. The product is indicated for the treatment of corticosteroid-respon...

2/16/2024
AllergyBreakingDealsDry EyePharmaSurgical
Harrow Licenses Rights to Five Drugs to Apotex for Canada
Harrow Licenses Rights to Five Drugs to Apotex for Canada

Harrow reported Feb. 15 that it had licensed to Apotex exclusive marketing and distribution rights to Verkasia and over-the-counter Cationorm Plus in the Canadian market. In addition, Apotex will p...

2/9/2024
BreakingDealsGlaucomaPharma
Nicox Licenses NCX 470 (Bimatoprost) Drop for Glaucoma to Kowa for Japan for $3.2 Million Up Front
Nicox Licenses NCX 470 (Bimatoprost) Drop for Glaucoma to Kowa for Japan for $3.2 Million Up Front

France’s Nicox announced Feb. 8 that it had signed a deal granting Japanese drug company Kowa exclusive Japanese rights to develop and commercialize Nicox’ NCX 470 (0.1% bimatoprost) eye drop for g...

2/9/2024
BreakingCataractDealsSurgical
Omeros Changes Up Royalty Agreement with DRI Healthcare for Additional $115 Million
Omeros Changes Up Royalty Agreement with DRI Healthcare for Additional $115 Million

Seattle-based Omeros reported Feb. 1 that it had changed up its agreement with DRI Healthcare Trust for Omidria royalties. DRI, based in Toronto, Canada, has paid Omeros an additional $115 million ...

2/9/2024
BreakingDealsRetina
Kiora Licenses Retinal Candidate to Théa Open Innovation in Potential $301M Deal
Kiora Licenses Retinal Candidate to Théa Open Innovation in Potential $301M Deal

Encinitas, California-based Kiora Pharmaceuticals reported Jan. 31 that it had granted Théa Open Innovation exclusive worldwide development and commercialization rights, excluding Asia, to KIO-301 ...

2/2/2024
BreakingDealsFundingPharmaRetina
New Company Eyconis Formed to Develop Ascendis Pharma's Ophthalmology Assets
New Company Eyconis Formed to Develop Ascendis Pharma's Ophthalmology Assets

Denmark’s Ascendis Pharma announced Jan. 29 that it had founded Eyconis, a separate company to develop and commercialize its ophthalmic assets globally. The company is launching with a $150 million...

1/26/2024
BiosimilarsBreakingDealsRetina
Sandoz Acquires Ranibizumab Biosimilar Cimerli from Coherus for $170 Million Up Front
Sandoz Acquires Ranibizumab Biosimilar Cimerli from Coherus for $170 Million Up Front

Swiss drugmaker Sandoz announced Jan. 22 that it had signed an agreement to acquire the US ranibizumab (Lucentis) biosimilar Cimerli from Coherus BioSciences for $170 million up front. The deal inc...

1/26/2024
BreakingClinical TrialDeals
Iuvo BioScience Acquires Promedica International, Broadening Ophthalmic CRO Expertise
Iuvo BioScience Acquires Promedica International, Broadening Ophthalmic CRO Expertise

Rochester, New York-based Iuvo BioScience, a clinical research organization (CRO) that specializes in ophthalmology, reported Jan. 18 that it had acquired privately held Promedica International, an...

1/26/2024
BreakingDealsPharmaRetina
BlueRock Exercises Option to License Retinal Cell Therapy Candidate from Fujifilm and Opsis
BlueRock Exercises Option to License Retinal Cell Therapy Candidate from Fujifilm and Opsis

Bayer subsidiary BlueRock Therapeutics announced Jan. 23 that it had exercised its option to license OpCT-001, an induced pluripotent stem cell (iPSC) derived cell therapy candidate for primary pho...

1/26/2024
BreakingDealsPharmaRetina
Abpro to Gain Nasdaq Listing in Merger with SPAC, Has Retinal Candidate in Pipeline
Abpro to Gain Nasdaq Listing in Merger with SPAC, Has Retinal Candidate in Pipeline

Privately held Abpro reported Jan. 22 that it will gain a listing on the Nasdaq through a merger with Atlantic Coastal Acquisition Corp. II, a special purpose acquisition company (SPAC) based in Ne...

1/23/2024
DealsFundingNewsletter
Ophthalmology Sees Large Acquisitions in 2023; Dollar Total Reaches Three-Year High
Ophthalmology  Sees Large Acquisitions in 2023; Dollar Total Reaches Three-Year High

Ophthalmic deals in 2023 reached nearly $12.3 billion and included 78 transactions. This compares with $5.7 billion in 2022 and $8.5 billion in 2021. Mergers and acquisitions totaled $8.9 billion; ...

1/23/2024
DealsMyopiaNewsletterRefractive
Eyenovia Reacquires Rights to MicroPine in US, Canada from Bausch + Lomb
Eyenovia Reacquires Rights to MicroPine  in US, Canada from Bausch + Lomb

Eyenovia announced Jan. 16 that it had reacquired the rights to pediatric myopia candidate MicroPine in the US and Canada from Bausch + Lomb. The investigational formulation of atropine, intended f...

1/23/2024
DealsNewsletterRetinaSurgical
2023 in Review: Zeiss Fills Retina Gap with $1.1 Billion Acquisition of DORC
2023 in Review: Zeiss Fills Retina Gap with $1.1 Billion Acquisition of DORC

Carl Zeiss Meditec announced in December that Zeiss had agreed to acquire Netherlands-based Dutch Ophthalmic Research Center (DORC) from investment firm Eurazeo for €985 million ($1.1 billion). Eua...

1/23/2024
DealsIndustryNewsletterRetina
2023 in Review: Astellas’ Deal for Iveric Bio Tops Ophthalmic Acquisitions in 2023
2023 in Review: Astellas’ Deal for Iveric Bio Tops Ophthalmic Acquisitions in 2023

Japanese drugmaker Astellas made the single largest transaction in the 2023 ophthalmic market when it acquired Iveric Bio for $5.9 billion. The deal was announced April 30 and closed on July 11, wh...

1/23/2024
DealsGene TherapyNewsletterRetina
Janssen Purchases Remaining Rights for XLRP Candidate from MeiraGTx for $415 Million
Janssen Purchases  Remaining Rights  for XLRP Candidate from MeiraGTx for $415 Million

Janssen Pharmaceuticals has purchased from MeiraGTx the remaining rights for development, manufacturing, and commercializa-tion of botaretigene sparoparvovec (bota-vec) for $415 million, MeiraGTx r...

1/23/2024
CataractCornealDealsDry EyeGene TherapyGlaucomaIndustryLaserNewsletterOCTRegulationRetina
January 2024 Ophthalmic News Briefs
January 2024 Ophthalmic News Briefs

Maker of Sophi Phaco Machines UK-based Rayner announced Jan. 17 that it had acquired Switzerland’s This AG, the maker of Sophi phacoemulsification machines. No financial details were disclosed. Sop...

1/19/2024
BreakingCataractDealsSurgical
Rayner Acquires Switzerland-Based This AG, Maker of Sophi Phaco Machines
Rayner Acquires Switzerland-Based This AG, Maker of Sophi Phaco Machines

UK-based Rayner announced Jan. 17 that it had acquired Switzerland’s This AG, the maker of Sophi phacoemulsification machines. No financial details were disclosed. Sophi phaco machines are battery-...

1/19/2024
BreakingDealsMyopiaPharma
Eyenovia Reacquires Rights to MicroPine in US, Canada from Bausch + Lomb
Eyenovia Reacquires Rights to MicroPine in US, Canada from Bausch + Lomb

Eyenovia announced Jan. 16 that it had reacquired the rights to pediatric myopia candidate MicroPine in the US and Canada from Bausch + Lomb. The investigational formulation of atropine, intended f...

1/5/2024
BreakingDealsFundingIndustryRetina
Oxurion Avoids Bankruptcy, Will Focus on Preclinical Programs in GA
Oxurion Avoids Bankruptcy, Will Focus on Preclinical Programs in GA

Belgium’s Oxurion announced Dec. 28 that it had avoided bankruptcy through an agreement with its main creditor, Atlas Special Opportunities. Atlas will continue to fund Oxurion under an existing 20...

1/5/2024
BreakingDealsDry Eye
Nordic Pharma Subsidiary Acquires Visant Medical, Will Launch Lacrifill for Dry Eye in US
Nordic Pharma Subsidiary Acquires Visant Medical, Will Launch Lacrifill for Dry Eye in US

Nordic Pharma subsidiary Amring Pharmaceuticals announced Dec. 18 that it had completed its acquisition of Visant Medical. Visant received US FDA 510(k) clearance in 2022 for its Lacrifill cross-li...

12/29/2023
BreakingDealsGene TherapyRetina
Janssen Buys Remaining Rights for XLRP Candidate from MeiraGTx for $415 Million
Janssen Buys Remaining Rights for XLRP Candidate from MeiraGTx for $415 Million

Janssen Pharmaceuticals has purchased from MeiraGTx the remaining rights for development, manufacturing, and commercialization of botaretigene sparoparvovec (bota-vec) for $415 million, MeiraGTx re...

12/29/2023
BreakingCataractDealsGlaucomaMergersPharma
Ophthalmic Drugmaker Visiox to Merge with SPAC to Gain Nasdaq Listing
Ophthalmic Drugmaker Visiox to Merge with SPAC to Gain Nasdaq Listing

Privately held Visiox Pharmaceuticals reported Dec. 27 that it will gain a listing on the Nasdaq through a merger with PowerUp Acquisition Corp., a special purpose acquisition company (SPAC) based ...

12/29/2023
BreakingDealsStudy
ECM to Collaborate with Pitt’s Fox Center on Restoring Optic Nerve Damage
ECM to Collaborate with Pitt’s Fox Center on Restoring Optic Nerve Damage

ECM Therapeutics, of Warrendale, Pennsylvania, reported Dec. 19 that it would collaborate with the Louis J. Fox Center for Vision Restoration on work to restore vision following optic nerve damage....

12/20/2023
BreakingDealsDiagnosticRetina
RetinAI to Provide Connectivity for RIMR Consortium Targeting AMD Biomarkers
RetinAI to Provide Connectivity for RIMR Consortium Targeting AMD Biomarkers

RetinAI reported Nov. 29 that it had joined a global nonprofit consortium of physicians, researchers, and industry partners working to define optimal biomarkers and endpoints in age-related macular...

12/15/2023
BreakingCataractDealsRetinaSurgical
Carl Zeiss Meditec Acquires DORC for $1.1 Billion
Carl Zeiss Meditec Acquires DORC for $1.1 Billion

Carl Zeiss Meditec announced Dec. 15 that it had agreed to acquire Netherlands-based Dutch Ophthalmic Research Center (DORC) from investment firm Eurazeo, of Paris. DORC, founded in 1983, is a lead...

12/15/2023
BreakingDealsDiagnosticIndiaOCT
Aurolab to Develop Kubota’s At-home OCT Device for South Asia Markets
Aurolab to Develop Kubota’s At-home OCT Device for South Asia Markets

Seattle-based Kubota Vision reported Dec. 6 that it agreed to provide Aurolab, of India, with an exclusive license to develop, manufacture, and distribute eyeMo, Kubota’s low-cost, home-based, self...

12/14/2023
AIDealsDigitalNewsletter
Genentech, Nvidia Combine AI Expertise to Accelerate Drug Development
Genentech, Nvidia Combine AI Expertise to Accelerate Drug Development

Genentech and Nvidia reported Nov. 21 that the two companies had formed a multi-year strategic research collaboration to accelerate Genentech’s proprietary algorithms and speed drug development. Ge...

12/14/2023
CataractClinical TrialDealsDiagnosticGene TherapyGlaucomaIndustryNewsletterRegulationRetinaTelehealth
December 2023 Ophthalmic News Briefs
December 2023 Ophthalmic News Briefs

Enzene Biosciences, based in Pune, India, announced in November that it had launched a ranibizumab biosimilar for the treatment of wet age-related macular degeneration (AMD). The product references...

12/1/2023
AIBreakingDealsPharma
Genentech, Nvidia Combine AI Expertise to Accelerate Drug Development
Genentech, Nvidia Combine AI Expertise to Accelerate Drug Development

Genentech and Nvidia reported Nov. 21 that the two companies had formed a multi-year strategic research collaboration to accelerate Genentech’s proprietary algorithms and speed drug development. Ge...

11/22/2023
BreakingDealsDiagnostic
Keeler and Long Grove Pharmaceuticals Enter Agreement for Distribution of Ak-fluor 
Keeler and Long Grove Pharmaceuticals Enter Agreement for Distribution of Ak-fluor

Ophthalmic company Keeler announced Nov. 15 that it had formed a partnership with Long Grove Pharmaceuticals to distribute Ak-fluor (fluorescein injection) for diagnostic fluorescein angiography. L...

11/21/2023
DealsGlaucomaNewsletter
Stuart Therapeutics Licenses its Glaucoma Neuroprotection Candidate to Glaukos
Stuart Therapeutics Licenses its Glaucoma Neuroprotection Candidate to Glaukos

Stuart Therapeutics announced Oct. 18 that it had granted Glaukos exclusive worldwide rights to develop and commercialize Stuart’s ST-113 drug candidate for neuroprotection in glaucoma. ST-113 is a...

11/21/2023
DealsDry EyeNewsletterPharma
AbbVie Signs Option Deal with Aldeyra for License to Develop Reproxalap
AbbVie Signs Option Deal with Aldeyra for License to Develop Reproxalap

Aldeyra Therapeutics announced Nov. 1 that AbbVie had signed an exclusive option agreement to license to develop, manufacture, and commercialize reproxalap, Aldeyra’s candidate in development for d...

11/21/2023
ChinaDealsDiagnosticDry EyeGene TherapyGenericsGlaucomaIndustryNewsletterPresbyopiaRegulationRetinaSurgical
November 2023 Ophthalmic News Briefs
November 2023 Ophthalmic News Briefs

Specialty pharma company Padagis announced Oct. 13 the launch of its brinzolamide ophthalmic suspension, a generic version of Novartis’ Azopt for glaucoma. Padagis, with offices in the US and Israe...

11/17/2023
BreakingDealsMergersPresbyopia
Lenz Plans Merger with Graphite Bio to Gain Nasdaq Listing, Advance Presbyopia Drop Candidate
Lenz Plans Merger with Graphite Bio to Gain Nasdaq Listing, Advance Presbyopia Drop Candidate

Privately held Lenz Therapeutics announced Nov. 15 that it had entered into an agreement to merge with Nasdaq-listed Graphite Bio in an all-stock transaction. The combined company would take the Le...

11/17/2023
BreakingDealsDiagnosticOptometryTelehealth
Visionix Forms Strategic Alliance with 20/20Now to Expand Tele-optometry
Visionix Forms Strategic Alliance with 20/20Now to Expand Tele-optometry

Visionix’ US division announced Nov. 10 that it had entered into a strategic alliance with 20/20Now to bring tele-optometry to more optical retailers. 20/20Now, of Holbrook, New York, offers a soft...

11/3/2023
BreakingDealsDry Eye
AbbVie Signs Option Agreement with Aldeyra for License to Develop and Commercialize Reproxalap
AbbVie Signs Option Agreement with Aldeyra for License to Develop and Commercialize Reproxalap

Aldeyra Therapeutics announced Nov. 1 that AbbVie had signed an exclusive option agreement to license to develop, manufacture, and commercialize reproxalap, Aldeyra’s candidate in development for d...

11/3/2023
BreakingDealsDiagnosticRetina
Aeye Health, Topcon Partner to Deliver AI-Aided Point-of-Care Screening for DR
Aeye Health, Topcon Partner to Deliver AI-Aided Point-of-Care Screening for DR

Aeye Health and Topcon’s diabetic point-of-care eye exam arm, Topcon Screen, announced Oct. 27 that they would partner to deliver artificial intelligence-aided screening for diabetic retinopathy (D...

10/27/2023
BreakingDealsGlaucomaPharma
Stuart Therapeutics Licenses its Glaucoma Neuroprotection Candidate to Glaukos
Stuart Therapeutics Licenses its Glaucoma Neuroprotection Candidate to Glaukos

Stuart Therapeutics announced Oct. 18 that it had granted Glaukos exclusive worldwide rights to develop and commercialize Stuart’s ST-113 drug candidate for neuroprotection in glaucoma. ST-113 is a...

10/24/2023
DealsDry EyeGene TherapyNewsletter
Acquisitions and OUS Investments Drive Ophthalmic Deals in Third Quarter of 2023
Acquisitions and OUS Investments Drive Ophthalmic Deals in Third Quarter of 2023

Ophthalmic deals in Q3-2023 reached nearly $2.8 billion and involved 22 transactions. This compares with $6.9 billion from 24 transactions in Q2-2023 and $1.0 billion from 20 transactions in Q3-202...

10/24/2023
CataractClinical TrialDealsDiagnosticDry EyeGene TherapyGenericsIOLIndustryMicroscopesNewsletterOcular CancerRegulationRetina
October 2023 Ophthalmic News Briefs
October 2023 Ophthalmic News Briefs

Théa Pharma, the US subsidiary of France’s Laboratoires Théa, announced the launch Sept. 26 of once-daily Iyuzeh (latanoprost ophthalmic solution) 0.005% in the US market. Iyuzeh is the first prese...

10/20/2023
BreakingDeals
Fera Reaches Deal with Canada’s LSL to Import Erythromycin Eye Ointment for Newborns
Fera Reaches Deal with Canada’s LSL to Import Erythromycin Eye Ointment for Newborns

Canada’s LSL Pharma Group announced Oct. 18 that it had reached a deal with US specialty pharmaceutical company Fera to import erythromycin ophthalmic ointment (5mg/g) for the treatment of newborns...

10/20/2023
BreakingDealsGene TherapyRetina
SpliceBio, Spark Therapeutics to Collaborate on Gene Therapy Targeting Inherited Retinal Disease
SpliceBio, Spark Therapeutics to Collaborate on Gene Therapy Targeting Inherited Retinal Disease

Spain’s SpliceBio announced Oct. 17 that it had signed an agreement with Spark Therapeutics to utilize SpliceBio’s protein splicing platform to develop a gene therapy for an undisclosed inherited r...

10/13/2023
BreakingChinaDealsIOL
AffaMed Licenses Evolux Enhanced Monofocal IOL from SIFI for Greater China Market
AffaMed Licenses Evolux Enhanced Monofocal IOL from SIFI for Greater China Market

China’s AffaMed Technologies announced Oct. 10 that it had entered into an agreement with SIFI, of Italy, to manufacture, develop, and commercialize SIFI’s Evolux enhanced monofocal intraocular len...

10/6/2023
BreakingDealsDiagnosticRetina
Zeiss Partners With Boehringer Ingelheim to Improve Diagnosis and Treatment of Eye Disease
Zeiss Partners With Boehringer Ingelheim to Improve Diagnosis and Treatment of Eye Disease

German companies Zeiss and Boehringer Ingelheim reported Oct. 2 that they would collaborate long-termon developing predictive analytics to foster earlier detection of eye disease and more personali...

9/29/2023
BreakingDealsGene TherapyRetina
Kriya Licenses Everads’ Suprachoroidal Delivery Technology for Gene Therapy Candidates Targeting Complement Cascade
Kriya Licenses Everads’ Suprachoroidal Delivery Technology for Gene Therapy Candidates Targeting Complement Cascade

Israel’s Everads Therapy announced Sept. 27 that it had entered into an agreement with Kriya Therapeutics to advance Kriya’s portfolio of gene therapies for retinal diseases using Everads’ supracho...

9/29/2023
BreakingDealsGene TherapyRetina
ProQR’s Deal with Théa to Acquire Ophthalmic Assets is Terminated
ProQR’s Deal with Théa to Acquire Ophthalmic Assets is Terminated

Netherlands-based ProQR Therapeutics announced Sept. 27 that a deal with France’s Laboratoires Théa to acquire ProQR’s late-stage ophthalmic assets had been terminated. Théa had agreed in August 20...

9/29/2023
BreakingChinaDealsDry EyeEurope
CS Pharmaceuticals acquires AxeroVision and Cream-Based Dry Eye Candidate
CS Pharmaceuticals acquires AxeroVision and Cream-Based Dry Eye Candidate

London-based CS Pharmaceuticals reported July 28 that it had acquired AxeroVision, of Carlsbad, California, and its AXR-270 candidate for dry eye disease. The company did not report financial detai...

9/22/2023
BreakingDealsPharma
Novartis Readies Spinout of Sandoz, a Leading Provider of Generic Ophthalmic Drugs
Novartis Readies Spinout of Sandoz, a Leading Provider of Generic Ophthalmic Drugs

Swiss company Novartis reported Sept. 15 that its shareholders had approved its spinoff of Sandoz, its generics and biosimilars business. The target date for the spinoff is Oct. 4. Sandoz is a lead...

9/21/2023
AcquisitionsDealsEuropeNewsletterSurgical
BVI Expands Presence in Spain and Portugal with Acquisition of Medical Mix
BVI Expands Presence in Spain and Portugal with Acquisition  of Medical Mix

BVI Medical announced Sept. 6 that it had acquired Medical Mix, a leading supplier of ophthalmic surgical devices in Spain and Portugal. No financial details were provided. Medical Mix, of Barcelon...

9/21/2023
DealsNewsletterRegulation
Amgen to Complete Horizon Acquisition in Q4-2023 After Settling FTC Challenge
Amgen to Complete Horizon Acquisition in Q4-2023 After Settling FTC Challenge

The US Federal Trade Commission (FTC) will allow Amgen to acquire Horizon Therapeutics, after Amgen agreed in a consent order to several conditions related to how it will market its newly purchased...

9/21/2023
ChinaClinical TrialCornealDealsDiagnosticDry EyeEuropeGene TherapyIndustryNewsletterRefractiveRegulationRetinaSurgical
September 2023 Ophthalmic News Briefs
September 2023 Ophthalmic News Briefs

Carl Zeiss Meditec announced Aug. 23 that more than 8 million eyes had been treated with the company’s SMILE procedure through the first half of 2023. SMILE, short for small-incision lenticule extr...

9/15/2023
BreakingCornealDeals
NovaBay will Commercialize BioStem Amniotic Tissue Ocular Allograft as Avenova Allograft
NovaBay will Commercialize BioStem Amniotic Tissue Ocular Allograft as Avenova Allograft

NovaBay Pharmaceuticals and BioStem Technologies announced an agreement Sept. 11 under which NovaBay will commercialize BioStem’s ocular amniotic tissue allograft. No financial details for the deal...

9/15/2023
BreakingDealsGene TherapyRetina
Otsuka, ShapeTX Will Collaborate on Ocular Gene Therapy Candidates
Otsuka, ShapeTX Will Collaborate on Ocular Gene Therapy Candidates

Japan’s Otsuka Pharmaceutical and ShapeTX announced Sept. 7 that they would collaborate to develop intravitreally delivered adeno-associated virus (AAV) gene therapy candidates for ocular diseases,...

9/15/2023
BreakingDealsDry Eye
Link Biologics Partners with Théa Open Innovation to Develop Dry Eye Candidate
Link Biologics Partners with Théa Open Innovation to Develop Dry Eye Candidate

Link Biologics, of London, and France’s Théa Open Innovation announced Sept. 12 that they had agreed to co-develop Link’s topical anti-inflammatory candidate TSG6 for dry eye disease and other opht...

9/8/2023
AcquisitionsBreakingDealsEuropeSurgical
BVI Expands Presence in Spain and Portugal with Acquisition of Medical Mix
BVI Expands Presence in Spain and Portugal with Acquisition of Medical Mix

BVI Medical announced Sept. 6 that it had acquired Medical Mix, a leading supplier of ophthalmic surgical devices in Spain and Portugal. No financial details were provided. Medical Mix, of Barcelon...

9/1/2023
BreakingDealsRegulation
Amgen to Complete Horizon Acquisition in Q4-2023 After Settling FTC Challenge
Amgen to Complete Horizon Acquisition in Q4-2023 After Settling FTC Challenge

The US Federal Trade Commission (FTC) will allow Amgen to acquire Horizon Therapeutics, after Amgen agreed in a consent order to several conditions related to how it will market its newly purchased...

9/1/2023
BreakingDealsFundingRetina
CIRM Grants $12.4 Million to Regenerative Patch Technologies to Advance RPE Implant 
CIRM Grants $12.4 Million to Regenerative Patch Technologies to Advance RPE Implant

The California Institute for Regenerative Medicine (CIRM) announced July 27 that it had awarded a $12.4 million grant to Regenerative Patch Technologies (RPT) to support a Phase IIb clinical trial ...

9/1/2023
BreakingDealsGlaucomaIndustryLaserRetina
Iridex to Undergo Strategic Review
Iridex to Undergo Strategic Review

Iridex announced Aug. 29 that it would undergo a review of strategic alternatives, with Piper Sandler acting as financial advisor for the process. The Mountain View, California, ophthalmic laser co...

8/22/2023
DealsIndustryNewsletterRetina
Lurker Explains EyePoint’s Many Transitions as She Turns Over Reins
Lurker Explains EyePoint’s Many Transitions as She Turns Over Reins

Nancy Lurker, executive vice chair of EyePoint Pharmaceuticals, sat with Market Scope at the 2023 meeting of the American Society of Retina Specialists (ASRS) and reflected on the challenges of run...

8/22/2023
DealsNewsletterRetina
Laboratoires Théa to Acquire ProQR’s Ophthalmic Assets for €12.5M Up Front, Plus Milestone Payments
Laboratoires Théa to Acquire ProQR’s Ophthalmic Assets for €12.5M Up Front,  Plus Milestone Payments

Netherlands-based ProQR Therapeutics announced Aug. 1 that France’s Laboratoires Théa would acquire ProQR’s late-stage ophthalmic assets, sepofarsen and ultevursen, targeting inherited retinal dise...

8/22/2023
AICataractDealsGlaucomaIOLIndustryNewsletterPharmaRegulationRetinaSingle-Use
August 2023 Ophthalmic News Briefs
August 2023 Ophthalmic News Briefs

New York’s Icahn School of Medicine at Mount Sinai announced July 5 that it had launched the Center for Ophthalmic Artificial Intelligence and Human Health. The center will incorporate AI into educ...

8/18/2023
BreakingCataractDealsDry EyePharma
Eyenovia Licenses US Rights to Formosa’s Postsurgical Pain and Inflammation Candidate for $86 Million
Eyenovia Licenses US Rights to Formosa’s Postsurgical Pain and Inflammation Candidate for $86 Million

Taiwan-based Formosa Pharmaceuticals announced Aug. 16 that Eyenovia had licensed US rights to Formosa’s APP13007 (clobetasol propionate ophthalmic nanosuspension, 0.05%) for inflammation and pain ...

8/4/2023
BreakingDealsRetina
Laboratoires Théa to Acquire ProQR’s Ophthalmic Assets for €12.5 Million Up Front, Plus Milestone Payments, Royalties
Laboratoires Théa to Acquire ProQR’s Ophthalmic Assets for €12.5 Million Up Front, Plus Milestone Payments, Royalties

Netherlands-based ProQR Therapeutics announced Aug. 1 that France’s Laboratoires Théa would acquire ProQR’s late-stage ophthalmic assets, sepofarsen and ultevursen, targeting inherited retinal dise...

8/4/2023
BreakingDealsRegulation
Harrow Completes NDA Transfer for Vigamox, Launches Sales in the US
Harrow Completes NDA Transfer for Vigamox, Launches Sales in the US

Harrow announced July 31 that the transfer of rights to Vigamox from Novartis was complete and it had launched sales of the antibiotic eye drop in the US. Vigamox (moxifloxacin hydrochloride ophtha...

8/4/2023
BreakingCornealDealsEmerging
Verséa Ophthalmics Signs Deal to Distribute Celularity’s Amniotic Allografts in the US
Verséa Ophthalmics Signs Deal to Distribute Celularity’s Amniotic Allografts in the US

Celularity and Verséa Ophthalmics announced an exclusive US commercial agreement on July 27. Verséa will distribute Celularity’s Biovance and Biovance 3L for ocular surface disease and ocular surgi...

7/28/2023
BiosimilarsBreakingDealsRetina
Stada, Xbrane Look for New Partner After Deal with Bausch + Lomb for Ranibizumab Biosimilar Ends
Stada, Xbrane Look for New Partner After Deal with Bausch + Lomb for Ranibizumab Biosimilar Ends

Sweden’s Xbrane Biopharma and its partner Stada, of Germany, announced July 24 that they were looking for a new partner to commercialize their ranibizumab biosimilar in the US and Canada, after the...

7/25/2023
DealsFundingNewsletter
Venture Capital and OUS Investments in Ophthalmology Bounce Back in Q2-2023
Venture Capital and OUS Investments in Ophthalmology Bounce Back in Q2-2023

Ophthalmic deals in Q2-2023 surpassed $6.9 billion and involved 24 transactions. This compares with $1.8 billion from 16 transactions in Q1-2023 and $1.7 billion from 23 transactions in Q2-2022. Pu...

7/25/2023
DealsDry EyeNewsletter
Deals for Xiidra, Blink Drops Show Saunders is Again Banking on Dry Eye
Deals for Xiidra, Blink Drops Show Saunders is Again Banking on Dry Eye

Brent Saunders seems to be betting that what was good for Allergan’s eye care business will be good for Bausch + Lomb. Dry eye treatments dominated Allergan’s eye care business during Saunders’ ten...

7/25/2023
DealsGene TherapyNewsletterRetina
Astellas Licenses 4DMT’s Intravitreal Gene Therapy Vector in Deal Potentially Worth Nearly $1 Billion
Astellas Licenses 4DMT’s Intravitreal Gene Therapy Vector in Deal Potentially Worth Nearly $1 Billion

Japan’s Astellas Pharma and 4D Molecular Therapeutics announced July 10 that Astellas is licensing 4DMT’s R100 intravitreal gene therapy vector for one rare inherited ophthalmic disease, with optio...

7/25/2023
DealsDry EyeGlaucomaNewsletter
Santen Hands Over Rights for Eight Ophthalmic Pharma Products to Harrow, Visiox
Santen Hands Over Rights for Eight Ophthalmic Pharma Products to Harrow, Visiox

Japanese drugmaker Santen announced July 18 that Harrow had acquired US or Canadian commercial rights to seven of Santen’s branded eye drops, while Visiox Pharma had licensed US rights to Omlonti f...

Want to Read the Full Article?

Register A Corporate Account

A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.

Select one or more
Select one or more